文献速递肾移植肾小球疾病

Pegcetacoplan治疗肾移植后复发性C3G或原发性IC-MPGN的疗效与安全性

Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.
PubMed 文献 · Kidney Int Rep · 2024-10-10

NOBLE试验为前瞻性、2期、多中心、开放标签、随机对照研究,评估Pegcetacoplan在肾移植后复发性C3G或原发性IC-MPGN患者中的疗效与安全性。主要终点为第12周肾活检C3c染色减少。结果显示Pegcetacoplan组50%患者C3染色降低≥2个数量级,80%降低≥1个数量级,蛋白尿中位下降54.4%,eGFR稳定,耐受性良好。

要点

  • Pegcetacoplan可显著降低移植肾C3G/IC-MPGN复发患者的C3染色沉积。
  • 治疗12周蛋白尿中位下降54.4%,eGFR保持稳定。
  • 安全性良好,不良事件多为轻中度,无治疗中断或死亡。

核心结论

  • NOBLE试验表明Pegcetacoplan对肾移植后复发性C3G和原发性IC-MPGN患者具有疗效、安全性和耐受性。

研究设计与样本

  • NOBLE(NCT04572854)为前瞻性、2期、多中心、开放标签、随机对照试验,纳入肾移植后复发性C3G或IC-MPGN患者,比较Pegcetacoplan 1080 mg每周两次皮下输注联合标准治疗与仅标准治疗。
  • 至第12周,10例接受Pegcetacoplan,3例仅接受标准治疗。

主要发现

  • 第12周,Pegcetacoplan组10例中5例(50%)C3染色降低≥2个数量级(其中4例染色为0且电镜沉积物消失),8例(80%)降低≥1个数量级;仅标准治疗组3例中1例(33%)染色降低。
  • Pegcetacoplan组10例中8例(80.0%)C3G组织学活动评分平均下降>54%。
  • 基线uPCR≥1000 mg/g的Pegcetacoplan治疗患者第12周蛋白尿中位(IQR)下降54.4%(-56.33至-53.95)。
  • Pegcetacoplan治疗患者eGFR稳定,血浆sC5b-9降低,血清C3升高。
  • Pegcetacoplan耐受性良好,多数不良事件为轻/中度,无停药、退出治疗或死亡报告。

临床怎么用

  • 对于肾移植后复发性C3G或原发性IC-MPGN患者,Pegcetacoplan可能作为减少C3沉积和蛋白尿的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) have high risks for disease recurrence and allograft loss in transplant kidneys. Pegcetacoplan (targeted complement 3 [C3]/C3b inhibitor) may prevent excessive deposition of C3 and complement 5 [C5] breakdown products and associated renal damage. METHODS: NOBLE (NCT04572854) is a prospective, phase 2, multicenter, open-label, randomized controlled trial evaluating the efficacy and safety of pegcetacoplan in posttransplant patients with recurrent C3G or IC-MPGN. The primary end point was reduction in C3c staining on renal biopsy at week 12 for patients who received either pegcetacoplan 1080 mg twice weekly by subcutaneous infusion plus standard-of-care (SOC) or SOC only. RESULTS: Ten patients received pegcetacoplan and 3 received SOC only through week 12. At week 12, 5 of 10 pegcetacoplan-treated patients (50%) achieved ≥2 orders of magnitude (OOM) reduction in C3 staining (4 of these 5 had 0 staining and absent electron microscopy deposits) and 8 of 10 (80%) achieved ≥1 OOM reduction; 1 of 3 (33%) SOC-only patients showed staining reduction. Mean C3G histology activity score decreased by >54% in 8 of 10 pegcetacoplan-treated patients (80.0%). Pegcetacoplan-treated patients with baseline urine protein-to-creatinine ratio (uPCR) ≥1000 mg/g showed a median (interquartile range [IQR]) 54.4% (-56.33 to -53.95) reduction in proteinuria at week 12. In addition, pegcetacoplan-treated patients showed stable estimated glomerular filtration rate (eGFR), reduced plasma sC5b-9, and increased serum C3. Pegcetacoplan was well-tolerated and most adverse events were mild/moderate. No discontinuations, treatment withdrawals, or deaths were reported. CONCLUSION: NOBLE demonstrated efficacy, safety, and tolerability of pegcetacoplan for patients with posttransplant recurrent C3G and primary IC-MPGN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bomback AS, Daina E, Remuzzi G, et al. Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis. Kidney Int Rep. 2024. PMID: 39810766. doi:10.1016/j.ekir.2024.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。